The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Approves Riabni, a Rituxumab Biosimilar, to Treat Patients with RA

FDA Approves Riabni, a Rituxumab Biosimilar, to Treat Patients with RA

July 13, 2022 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

On June 3, the U.S. Food & Drug Administration (FDA) approved rituximab-arrx (Riabni) in combination with methotrexate to treat adults with moderate or severe, active rheumatoid arthritis (RA) for whom one or more tumor necrosis factor agonist therapies had proved inadequate.1,2 Rituximab-arrx is biosimilar to rituximab (Rituxan), an anti-CD20 monoclonal antibody. In the same dosage form and administration route as rituximab, rituximab-arrx was previously approved by the FDA for the following indications: non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis and microscopic polyangiitis.2,3

You Might Also Like
  • FDA Approves New Rituximab Biosimilar & Anakinra to Treat a Rare Disease
  • FDA Approves Cyltezo, an Interchangeable Biosimilar to Humira
  • U.S. FDA Approves Biosimilar to Etanercept
Also By This Author
  • Patients with OA Respond to Low-Dose SoluMatrix Meloxicam; Off-Label Use of Ketoconazole Results in Death

Background

This approval was based on the results of a double-blind, placebo-controlled study that evaluated the efficacy and safety of rituximab-arrx against its reference product, rituximab.4 The study participants were at least 18 years old, had been diagnosed with active RA according to ACR criteria and had at least eight swollen joints and eight tender joints. The study also examined the treatment’s pharmacokinetics and immunogenicity. Its primary end point was the change from baseline in Disease Activity Score-28 for RA with C-reactive protein (DAS28-CRP) at week 24.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

A total of 311 patients were randomized to receive either rituximab-arrx, rituximab approved in the U.S. (rituximab-U.S.) or the European Union (rituximab-E.U.). The patients who received rituximab-U.S. were transitioned to rituximab-arrx during the second part of the study.

The primary end point was within the predefined equivalence margin. The safety, immunogenicity and pharmacokinetics of rituximab-arrx were all similar to that of its reference product. No new safety signals were found.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The FDA approval means rituximab-arrx is approved for rheumatoid arthritis and all other indications of the reference product rituximab. However, this biosimilar agent does not have an interchangeability designation with other rituximab products in the U.S.5

Currently, two other agents that are biosimilar to rituximab are FDA approved, rituximab-pvvr (Ruxience) and rituximab-abbs (Truxima).6


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Supplemental biologics license application approval letter: Riabni (rituximab-arrx). U.S. Food & Drug Administration. 2020 Jun 3.
  2. Biologics license application approval letter: Riabni (rituximab-arrx). U.S. Food & Drug Administration. 2020 Dec 17.
  3. Highlights of prescribing information: Riabni (rituximab-arrx). U.S. Food & Drug Administration. 2020 Jun 3.
  4. News release: FDA approves Riabni (rituximab-arrx), a biosimilar to Rituxan (rituximab), for adults with moderate to severe rheumatoid arthritis. Amgen Inc. 2022 Jun 6.
  5. FDA purple book: Database of licensed biologic products—Riabni. U.S. Food & Drug Administration. 2022.
  6. Biosimilar product information. U.S. Food & Drug Administration. 2022 Feb 25.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Biosimilars, FDA, FDA approval, Rheumatoid Arthritis (RA), Riabni, Rituxan, rituximab, rituximab-arrx, U.S. Food and Drug Administration (FDA)

You Might Also Like:
  • FDA Approves New Rituximab Biosimilar & Anakinra to Treat a Rare Disease
  • FDA Approves Cyltezo, an Interchangeable Biosimilar to Humira
  • U.S. FDA Approves Biosimilar to Etanercept
  • FDA Approves Adalimumab-atto, a Biosimilar of Humira

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)